目的 探究苦碟子注射液联合曲美他嗪治疗冠心病心绞痛的临床疗效。方法 选取2018年1月-2020年12月河南科技大学第一附属医院收治的100例冠心病患者，随机分为对照组（50例）和治疗组（50例）。对照组口服盐酸曲美他嗪片，20 mg/次，3次/d。治疗组在对照组基础上静脉注射苦碟子注射液，30 mL加入250 mL生理盐水，1次/d。两组患者连续治疗1个月。观察两组患者临床疗效，比较治疗前后两组患者临床症状改善情况、血浆纤维蛋白原、血浆黏度、中医症候评分。结果 治疗后，治疗组临床有效率为92.00%，显著高于对照组的82.00%（P<0.05）。治疗后，两组患者心绞痛发作频率和持续时间以及硝酸甘油用量均明显减少（P<0.05），且治疗组明显少于对照组（P<0.05）。治疗后，两组患者血浆纤维蛋白原和血浆黏度水平明显下降（P<0.05），且治疗组明显低于对照组（P<0.05）。治疗后，两组中医症候评分明显下降（P<0.05），且治疗组明显低于对照组（P<0.05）。结论 苦碟子注射液联合曲美他嗪治疗冠心病心绞痛能够改善患者临床症状和血液流变学指标，提高临床有效率。

Objective To explore the efficacy of Kudiezi Injection combined with trimetazidine in treatment of angina pectoris of coronary heart disease. Methods Patients (100 cases) with angina pectoris of coronary heart disease in the First Affiliated Hospital of Henan Science & Technology University from January 2018 to December 2020 were randomly divided into control (50 cases) and treatment (50 cases) groups. Patients in the control group were po administered with Trimetazidine Hydrochloride Tablets, 20 mg/time, three times daily. Patients in the treatment group were iv administered with Kudiezi Injection, 30 mL added into normal saline 250 mL, once daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacy was evaluated, the improvement of clinical symptoms, plasma fibrinogen, plasma viscosity, and the TCM syndrome scores in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 92.00%, which was significantly higher than 82.00% in the control group (P<0.05). After treatment, the frequency and duration of angina pectoris and the dosage of nitroglycerin in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly less than those in the control group (P<0.05). After treatment, plasma fibrinogen and plasma viscosity levels in two groups were significantly decreased (P<0.05), and the treatment group was significantly lower than the control group (P<0.05). After treatment, the TCM syndrome score in two groups were significantly decreased (P<0.05), and which in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Kudiezi injection combined with trimetazidine in the treatment of patients with angina pectoris of coronary heart disease can improve clinical symptoms and hemodynamic indicators, and improve clinical effectiveness.

R972

河南科技大学青年科学基金资助项目（2018QN047）